Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsAvadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.
NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.
Ophthalmology in 2025: Year in Review
Increases in Physician Attrition Rates Could Worsen Shortages
Hormonal Disorders in 2025: Year in Review
1.
An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.
2.
Q&A: How early cancer screening could save Canada nearly half a billion dollars over patients' lifetimes
3.
Can taking vitamin D supplements every day lower the mortality rate from cancer?
4.
Elder Abuse: Red Flags to Look Out For While Receiving Care.
5.
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
1.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
2.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
3.
What Is A High MCV Level? Causes, Symptoms, And Treatment Options
4.
CAR T-Cell Therapy: Revolutionizing Hematologic Malignancies
5.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
2.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
3.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge